# US 2010/0167393 A1 · Modified human thymic stromal lymphopoietin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167393 A1
- Document ID: US20100167393A1
- Status: Published application
- Kind: A1
- Application number: 12/723,499
- Filed: 2010-03-12
- Published: 2010-07-01
- Earliest claimed: 2001-07-23
- Assignees: Immunex Corporation
- Inventors: Stewart D. LYMAN; Kirk P. VAN NESS; Raymond J. PAXTON
- Web page: https://patentgrep.com/patent/US20100167393A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/5418: {IL-7}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/52: Assays involving cytokines
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 4, wherein the polypeptide comprises a modification to inactivate the furin cleavage site RRKRK at position 127-131 of SEQ ID NO: 4.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 10.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 12.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 14.

### Claim 5 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 16.

### Claim 6 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 17.

### Claim 7 (depends on 1)

The nucleic acid molecule of claim 1 wherein the polynucleotide encodes a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO: 18.

### Claim 8 (depends on 2)

The nucleic acid of claim 2, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:10.

### Claim 9 (depends on 3)

The nucleic acid of claim 3, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:12.

### Claim 10 (depends on 4)

The nucleic acid of claim 4, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:14.

### Claim 11 (depends on 5)

The nucleic acid of claim 5, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:16.

### Claim 12 (depends on 6)

The nucleic acid of claim 6, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:17.

### Claim 13 (depends on 7)

The nucleic acid of claim 7, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:18.

### Claim 14 (depends on 1)

The nucleic acid of claim 1, wherein the polypeptide has at least 95% amino acid sequence identity to SEQ ID NO: 4.

### Claim 15 (depends on 1)

The nucleic acid molecule of claim 1, wherein the polynucleotide has at least 80% nucleotide sequence identity to SEQ ID NO: 3 or its complement.

### Claim 16 (depends on 15)

The nucleic acid molecule of claim 15, wherein the polynucleotide has at least 80% nucleotide sequence identity to SEQ ID NO: 9, 11, 13, or 15, or their complements.

### Claim 17 (depends on 1)

The nucleic acid molecule of claim 1, operably linked to a transcriptional or translational regulatory sequence.

### Claim 18 (depends on 17)

The nucleic acid molecule of claim 17, wherein said transcriptional or translational regulatory sequence comprise a transcriptional promoter or enhancer.

### Claim 19 (depends on 1)

A vector comprising the nucleic acid molecule of claim 1.

### Claim 20 (depends on 1)

A host cell genetically engineered to express the nucleic acid molecule of claim 1.

### Claim 21 (depends on 20)

The host cell of claim 20, wherein the host cell is a mammalian cell.
